Lexaria Bioscience Corp.
LEXX
$0.60
$0.034.44%
NASDAQ
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Net Income | 46.56% | 41.01% | -23.39% | -112.67% | -317.74% |
| Total Depreciation and Amortization | 189.13% | -39.50% | 15.32% | 74.31% | -59.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -55.29% | -16.10% | 270.17% | 22.44% | 2,019.23% |
| Change in Net Operating Assets | -178.25% | 376.69% | -286.04% | -550.98% | 260,300.00% |
| Cash from Operations | -44.46% | 63.90% | -39.69% | -183.07% | -141.75% |
| Capital Expenditure | -- | -- | 100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 53.05% | 61.36% | -493.61% | 11.82% | 51.05% |
| Cash from Investing | -93.19% | 86.51% | -126.87% | 11.82% | 51.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 25,917.95% | -20.05% | -- | -66.51% | -99.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 25,917.95% | -20.05% | -- | -66.51% | -99.66% |
| Foreign Exchange rate Adjustments | 121.62% | -78.13% | 409.52% | 3,200.00% | -281.20% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 152.63% | 57.06% | -42.38% | -150.01% | -158.49% |